Pharmacist Digest

STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion

STAT

DECEMBER 6, 2023

Facing the prospect of declining sales from two of its best-selling drugs, the company also acquired Immunogen and its ovarian cancer treatment for $10 billion last Thursday. The deal marks the second billion-dollar acquisition by AbbVie in under a week.

STAT+: U.K. sequencing study surfaces new findings about tumor DNA

STAT

JANUARY 10, 2024

The findings are already influencing clinical practice: It’s becoming standard for patients in the National Health Service with those tumors — including types of brain cancers, sarcomas, and ovarian cancers — to get their tumors sequenced. In a paper published Thursday morning in the U.K.,

STAT+: Cancer drug shortages widen disparities between big systems and small

STAT

SEPTEMBER 25, 2023

For months, oncologist Kristen Rice found herself scrambling for cisplatin and carboplatin, two key chemotherapies used for many different cancers including ovarian, bladder, and lung cancer. Pharmacy technicians would order more drugs each day to keep the clinic running until, one day, they couldn’t.

Pharmacy Technician

Pharmacy Technician Chemotherapy Hospitals

AstraZeneca’s Lynparza to dominate PARP inhibitors market with $4 bn in sales by 2027: GlobalData

Express Pharma

APRIL 25, 2024

In 2014, the FDA approved the first (adenosine diphosphate-ribose) polymerase (PARP) inhibitor AstraZeneca /Merck’s Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients who have received three or more prior lines of chemotherapy.

Chemotherapy

Mersana Therapeutics Reports US FDA’s Partial Clinical Hold on New Patient Enrollment of UpRi for Platinum-Sensitive Ovarian Cancer

PharmaShots

JUNE 16, 2023

Patients already enrolled can continue treatment The patient enrollment has been completed in the (UPLIFT) trial of UpRi for Pt-resistant ovarian cancer with results expected by early August.

STAT+: Pharmalittle: AbbVie buys Immunogen, maker of targeted cancer drugs; Novo sues two more compounders

STAT

NOVEMBER 30, 2023

… AbbVie will pay $10 billion for Immunogen, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology , STAT writes. Under Food and Drug Administration approval for advanced ovarian cancer in 2022. We hope you find these useful and have a smashing day.

Compounding

Compounding Compounding Pharmacies Chemotherapy

Datopotamab deruxtecan by Daiichi Sankyo for Epithelial Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 22, 2024

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Epithelial Ovarian Cancer.

Datopotamab deruxtecan by Daiichi Sankyo for Metastatic Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 22, 2024

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Ovarian Cancer.

TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment

Pharmafile

APRIL 10, 2024

TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer. The results were announced at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Farletuzumab ecteribulin by Eisai for Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 22, 2024

Farletuzumab ecteribulin is under clinical development by Eisai and currently in Phase II for Ovarian Cancer.

AbbVie agrees $10 billion oncology acquisition

European Pharmaceutical Review

DECEMBER 1, 2023

The antibody-drug conjugate is the first to be approved for platinum-resistant ovarian cancer (PROC) and show meaningful survival benefit for this form of the disease. As such, ongoing clinical development programmes are underway, according to AbbVie.

ADC startup ProfoundBio, led by Seagen veterans, raises $112M

BioPharma Dive

FEBRUARY 13, 2024

The Series B round will fund development of antibody-drug conjugates now in clinical testing, among them a rival to AbbVie’s ovarian cancer drug Elahere.

GSK enters exclusive license agreement with Hansoh for HS-20093

LifeProNow

DECEMBER 22, 2023

Under the agreement, GSK will obtain exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macau, and Taiwan) to progress clinical development and commercialisation of HS-20093. In October 2023, GSK and Hansoh entered into an agreement for HS-20089, a B7-H4 targeted ADC currently in phase II clinical trials in China.

First patient dosed in Scancell’s clinical trial for multiple cancers

Pharma Times

JUNE 13, 2022

First-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer and renal cancer

EC approves first-line ovarian cancer treatment

European Pharmaceutical Review

NOVEMBER 22, 2023

The small molecule treatment is indicated as a first-line maintenance treatment for individuals with advanced ovarian cancer regardless of their BRCA mutation status, who have responded to first-line platinum-based chemotherapy. ” The EC based its approval the Phase III ATHENA-MONO study results.

Chemotherapy

Chemotherapy Labelling

ProfoundBio secures $112m to advance ADC portfolio for cancer

Pharmaceutical Business Review

FEBRUARY 14, 2024

The latest capital will bolster ProfoundBio’s clinical and preclinical ADC programmes, primarily targeting solid tumour cancers. It is in Phase II trials for ovarian and endometrial cancers with pivotal studies in ovarian cancer expected to commence later this year.

STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast

STAT

DECEMBER 7, 2023

Facing the prospect of declining sales from two of its best-selling drugs, the company also acquired Immunogen and its ovarian cancer treatment for $10 billion last week. With

Drug Pricing

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Ovarian Cancer.

FDA Clears Trial of Non-Genetically Modified Natural Killer Cell Therapy

Pharmaceutical Commerce

JANUARY 23, 2024

NK010, which showed promising anti-tumor activity and safety in preclinical studies, will be evaluated in a Phase I clinical trial for ovarian cancer.

SLATE-001 by Gritstone Bio for Metastatic Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 17, 2024

SLATE-001 is under clinical development by Gritstone Bio and currently in Phase I for Metastatic Ovarian Cancer.

SGN-1 by Guangzhou Sinogen Pharmaceutical for Metastatic Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

JANUARY 22, 2024

SGN-1 is under clinical development by Guangzhou Sinogen Pharmaceutical and currently in Phase II for Metastatic Ovarian Cancer.

FDA grants accelerated approval for ImmunoGen’s ovarian cancer ADC

Pharmaceutical Technology

NOVEMBER 14, 2022

positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Elahere obtained the approval based on the findings on objective response rate (ORR) and duration of response (DOR) reported in the SORAYA clinical trial. positive platinum-resistant ovarian cancer.

ESMO 2022 – PAOLA-1, ovarian cancer, and treatment innovation

pharmaphorum

OCTOBER 27, 2022

Last month, pharmaphorum had the chance to speak with Dr Isabelle Ray-Coquard, professor of medical oncology (specialism sarcomas and GISTs) at the Centre Léon Bérard (CLB), a hospital 100% dedicated to cancer care and research. HRD (homologous recombination deficiency) is an important biomarker of the most advanced stages of ovarian cancer.

Chemotherapy

Chemotherapy Hospitals

Shaping the future of ovarian cancer diagnosis with femtech

pharmaphorum

AUGUST 13, 2021

Six years ago, research scientist Inbal Zafir-Lavie tragically lost her 38-year-old sister Hava Zafir to colorectal cancer. Due to her young age, doctors had been unable to detect the cancer through screening and by the time of diagnosis, it was too late. The loss of her sister had a profound effect on Inbal. Early detection.

HCW-9218 by HCW Biologics for Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

DECEMBER 25, 2023

HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Ovarian Cancer.

AbbVie to acquire ImmunoGen for approximately $10.1bn

Pharmafile

DECEMBER 1, 2023

AbbVie and ImmunoGen have announced that AbbVie will acquire ImmunoGen and its lead cancer therapy Elahere (mirvetuximab soratansine-gynx), a first in class antibody-drug conjugate (ADC) approved for the treatment of platinum-resistance ovarian cancer (PROC).

KSQ-4279 by F. Hoffmann-La Roche for Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

DECEMBER 26, 2023

KSQ-4279 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Ovarian Cancer.

CX-2029 by CytomX Therapeutics for Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Ovarian Cancer.

TAC-101 by Triumvira Immunologics for Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

JANUARY 4, 2024

TAC-101 is under clinical development by Triumvira Immunologics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase…

AbbVie agrees to acquire ImmunoGen for around $10.1bn

Pharmaceutical Business Review

DECEMBER 4, 2023

ELAHERE is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). “Together, AbbVie and ImmunoGen have the potential to transform the standard of care for people living with cancer.” Ovarian cancer is a leading reason for death amongst gynecological cancers in the US.

Labelling

STAT+: Foundation charges cancer patients $83,000 for unproven but promising experimental drug

STAT

MARCH 6, 2023

It has been more than 11 years since Julia Young was diagnosed with advanced ovarian cancer, and two years since it spread to her lymph system. Therapeutic vaccines represent the next frontier in cancer medicine. By her own account, she has already beaten the odds for how long most women survive the deadly disease.

Vaccines

Vaccines Bioethics Immunity Immunization

iOnctura receives orphan drug status for pancreatic cancer therapy

Pharmaceutical Business Review

MARCH 8, 2024

Following the analysis of cambritaxestat’s chemical and biological properties, including a promising non-clinical safety and efficacy profile, the US regulator granted the ODD status. Cambritaxestat is being developed as a therapy option for highly fibrotic cancers.

Chemotherapy

Chemotherapy Immunity Immunization

Cartherics grants licence for CTH-004 to Shunxi

Pharmaceutical Technology

MAY 1, 2023

Under the deal terms, Shunxi will have licence to develop, manufacture, and commercialise CTH-004 to treat several solid tumours including ovarian cancer in Greater China, including Hong Kong, Taiwan, Mainland China, and Macao. In animal models of ovarian cancer, it demonstrated promising results.

Luveltamab tazevibulin by Sutro Biopharma for Epithelial Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

DECEMBER 21, 2023

Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase I for Epithelial Ovarian Cancer.

TORL BioTherapeutics raises funds to develop new oncology therapies

Pharmaceutical Technology

APRIL 14, 2023

Clinical-stage biopharmaceutical company TORL BioTherapeutics has raised $158m in a Series B financing round for advancing the development of new biologics for cancer treatment. TORL BioTherapeutics is a newly formed, US-based company focused on the development of novel antibody-based therapeutics for cancer patients.

Compounding

Study: Participation in Clinical Trials Associated With Improved Overall Survival in Patients with Ovarian Cancer

Pharmacy Times

APRIL 12, 2023

Availability of clinical trials in the gynecologic cancer care space are increasing, but it is important to be mindful of current racial disparities.

Sacituzumab tirumotecan by Merck for Epithelial Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

DECEMBER 26, 2023

Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Epithelial Ovarian Cancer.

TORL BioTherapeutics secures $158m for oncology pipeline development

Pharmaceutical Business Review

APRIL 10, 2024

The funding will be used for the advancement of TORL’s new antibody-drug conjugate (ADC) oncology pipeline, including the clinical development. This Phase II trial aims to expedite the regulatory review and potential approvals for the ADC as a new treatment for patients with CLDN 6+ platinum-resistant ovarian cancer.

Drug Development

IDEAYA receives fast track designation for breast cancer therapy

Pharmaceutical Business Review

SEPTEMBER 28, 2023

The designation has been awarded for IDE161 to treat adult patients with advanced or metastatic hormone receptor-positive (HR+), Her2- breast cancer with germline or somatic BRCA 1/2 mutations. The post IDEAYA receives fast track designation for breast cancer therapy appeared first on Pharmaceutical Business review.

SH-105 by Shorla Oncology for Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

JANUARY 4, 2024

SH-105 is under clinical development by Shorla Oncology and currently in Pre-Registration for Ovarian Cancer.

SGN-1 by Guangzhou Sinogen Pharmaceutical for Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

DECEMBER 21, 2023

SGN-1 is under clinical development by Guangzhou Sinogen Pharmaceutical and currently in Phase II for Ovarian Cancer.

IDE-161 by Ideaya Biosciences for Metastatic Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

DECEMBER 22, 2023

IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Metastatic Ovarian Cancer.

Enzalutamide by Pfizer for Epithelial Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

DECEMBER 21, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase II for Epithelial Ovarian Cancer.

AstraZeneca reports positive results of drug combination in late-stage ovarian cancer trial

Pharmafile

APRIL 5, 2023

This combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy plus bevacizumab. The drug combination was assessed for newly diagnosed patients with advanced high-grade epithelial ovarian cancer without tumour BRCA mutations.

Chemotherapy

Chemotherapy Communication

STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion

STAT+: U.K. sequencing study surfaces new findings about tumor DNA

Trending Sources

STAT+: Cancer drug shortages widen disparities between big systems and small

AstraZeneca’s Lynparza to dominate PARP inhibitors market with $4 bn in sales by 2027: GlobalData

Mersana Therapeutics Reports US FDA’s Partial Clinical Hold on New Patient Enrollment of UpRi for Platinum-Sensitive Ovarian Cancer

STAT+: Pharmalittle: AbbVie buys Immunogen, maker of targeted cancer drugs; Novo sues two more compounders

Datopotamab deruxtecan by Daiichi Sankyo for Epithelial Ovarian Cancer: Likelihood of Approval

Datopotamab deruxtecan by Daiichi Sankyo for Metastatic Ovarian Cancer: Likelihood of Approval

TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment

Farletuzumab ecteribulin by Eisai for Ovarian Cancer: Likelihood of Approval

AbbVie agrees $10 billion oncology acquisition

ADC startup ProfoundBio, led by Seagen veterans, raises $112M

GSK enters exclusive license agreement with Hansoh for HS-20093

First patient dosed in Scancell’s clinical trial for multiple cancers

EC approves first-line ovarian cancer treatment

ProfoundBio secures $112m to advance ADC portfolio for cancer

STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Ovarian Cancer: Likelihood of Approval

FDA Clears Trial of Non-Genetically Modified Natural Killer Cell Therapy

SLATE-001 by Gritstone Bio for Metastatic Ovarian Cancer: Likelihood of Approval

SGN-1 by Guangzhou Sinogen Pharmaceutical for Metastatic Ovarian Cancer: Likelihood of Approval

FDA grants accelerated approval for ImmunoGen’s ovarian cancer ADC

ESMO 2022 – PAOLA-1, ovarian cancer, and treatment innovation

Shaping the future of ovarian cancer diagnosis with femtech

HCW-9218 by HCW Biologics for Ovarian Cancer: Likelihood of Approval

AbbVie to acquire ImmunoGen for approximately $10.1bn

KSQ-4279 by F. Hoffmann-La Roche for Ovarian Cancer: Likelihood of Approval

CX-2029 by CytomX Therapeutics for Ovarian Cancer: Likelihood of Approval

TAC-101 by Triumvira Immunologics for Ovarian Cancer: Likelihood of Approval

AbbVie agrees to acquire ImmunoGen for around $10.1bn

STAT+: Foundation charges cancer patients $83,000 for unproven but promising experimental drug

iOnctura receives orphan drug status for pancreatic cancer therapy

Cartherics grants licence for CTH-004 to Shunxi

Luveltamab tazevibulin by Sutro Biopharma for Epithelial Ovarian Cancer: Likelihood of Approval

TORL BioTherapeutics raises funds to develop new oncology therapies

Study: Participation in Clinical Trials Associated With Improved Overall Survival in Patients with Ovarian Cancer

Sacituzumab tirumotecan by Merck for Epithelial Ovarian Cancer: Likelihood of Approval

TORL BioTherapeutics secures $158m for oncology pipeline development

IDEAYA receives fast track designation for breast cancer therapy

SH-105 by Shorla Oncology for Ovarian Cancer: Likelihood of Approval

SGN-1 by Guangzhou Sinogen Pharmaceutical for Ovarian Cancer: Likelihood of Approval

IDE-161 by Ideaya Biosciences for Metastatic Ovarian Cancer: Likelihood of Approval

Enzalutamide by Pfizer for Epithelial Ovarian Cancer: Likelihood of Approval

AstraZeneca reports positive results of drug combination in late-stage ovarian cancer trial

Stay Connected